We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Cholesterol-Lowering Drugs May Lack Statins' Side Effects

By LabMedica International staff writers
Posted on 17 Mar 2011
A new generation of cholesterol-lowering drugs may be based on inhibitors of the enzyme squalene monooxygenase.

The current drugs of choice for reducing cholesterol levels, the statins, act by blocking the activity of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR). More...
Although statins are quite effective at reducing cholesterol, they are associated with potentially severe side effects such as intense muscle pain. These side effects may be due to the fact that blocking HMGR disrupts cholesterol production very early in the metabolic process. Squalene monooxygenase, on the other hand, forms a checkpoint much farther down the pathway where it uses NADPH and molecular oxygen to oxidize squalene to 2,3-oxidosqualene (squalene epoxide). At this point, it catalyzes the first oxygenation step in sterol biosynthesis, and is thought to be one of the rate-limiting enzymes in this pathway.

Another important point stressed in a paper published in the March 1, 2011, issue of the journal Cell Metabolism was that the activity of squalene monoxygenase was regulated by cholesterol itself and not by reaction byproducts or cofactors.

"Cholesterol has developed something of a bad name; so many people do not realize that it is actually essential for a healthy body. It is needed, for example, to make sex hormones and to help build the walls of every single cell in our bodies,” said senior author Dr. Andrew Brown, professor of biotechnology and biomolecular sciences at the University of New South Wales (Sydney, Australia). "The class of drugs most commonly used to lower cholesterol - statins – are the blockbusters of the pharmaceutical world and work by inhibiting HMGR. But HMGR is involved very early on in the assembly line, so inhibiting it affects all the other steps down the line – and other useful products it provides - and that can give rise in some people to unwanted side-effects, such as muscle pain.”

"What is exciting about this previously overlooked squalene monooxygenase enzyme is that it acts as a checkpoint much further down the assembly line, which should mean that it can be more specifically targeted at cholesterol production instead and leave the early part of the assembly line undisturbed,” said Dr. Brown.

Related Links:
University of New South Wales






Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Portable POCT Blood Gas Analyzer
BD100
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.